Salvianolic Acid B Inhibited LH2 Expression to Reduce Collagen Synthesis in Pulmonary Fibrosis
Journal of Cellular and Molecular Medicine · 2026-05 · 30 (10)
DOI: 10.1111/jcmm.71168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 25.05.2026. Verfasst von Songjun Shao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan Uni…. Hauptthemen laut MEDLINE: Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase, Benzofurans, Pulmonary Fibrosis, Collagen. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Program of Guizhou Province, the Health Commission of Guizhou Province.
Abstract (Originalsprache)
Collagen deposition and scar formation are hallmark features of fibrotic diseases. Lysyl hydroxylase 2 (PLOD2/LH2), a key collagen‐modifying enzyme, catalyses lysine hydroxylation at telopeptide sites to promote pyridinoline cross‐link formation, thereby enhancing collagen stability and matrix stiffness. However, the mechanisms regulating LH2 in pulmonary fibrosis (PF) are not fully understood. Here, we identify Salvianolic acid B (SAB) as a potent antifibrotic compound that targets LH2‐associated collagen cross‐linking. LH2 expression was markedly increased in alveolar epithelial cells and fibroblasts during PF, and its silencing attenuated TGF‐β1‐induced fibrotic protein expression. SAB reduced LH2 protein levels and significantly alleviated fibrotic remodelling, as evidenced by restored lung architecture and reduced collagen deposition. Mechanistically, the antifibrotic effects of SAB and LH2 were associated with inhibition of epithelial–mesenchymal transition (EMT), fibroblast‐to‐myofibroblast transition (FMT), and the Wnt/β‐catenin signalling pathway. This study indicates that pharmacological inhibition of LH2 by SAB effectively disrupts collagen cross‐linking and fibrotic progression, offering a promising therapeutic avenue for pulmonary fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, China.
- Department of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China.
ORCID-Profile: Songjun Shao, Fengming Luo
Förderung
- National Natural Science Foundation of China
- Science and Technology Program of Guizhou Province
- the Health Commission of Guizhou Province
- the Postdoctor Research Fund of West China Hospital, Sichuan University
- Health Commission of Guizhou Province
Zitieren
APA
Shao, S., Rao, S., Hu, S., Zhang, Y., Zheng, P., Li, C., Zhong, L., Long, Y., Tian, X., Tang, X., & Luo, F. (2026). Salvianolic Acid B Inhibited LH2 Expression to Reduce Collagen Synthesis in Pulmonary Fibrosis. Journal of Cellular and Molecular Medicine, 30(10). https://doi.org/10.1111/jcmm.71168
Vancouver
Shao S, Rao S, Hu S, Zhang Y, Zheng P, Li C, et al. Salvianolic Acid B Inhibited LH2 Expression to Reduce Collagen Synthesis in Pulmonary Fibrosis. Journal of Cellular and Molecular Medicine. 2026;30(10). doi:10.1111/jcmm.71168
BibTeX
@article{Shao2026,
author = {Shao, Songjun and Rao, Shanshan and Hu, Silu and Zhang, Yabin and Zheng, Peng and Li, Chunjie and Zhong, Lichun and Long, Yunzhi and Tian, Xin and Tang, Xiaoju and Luo, Fengming},
title = {Salvianolic Acid B Inhibited LH2 Expression to Reduce Collagen Synthesis in Pulmonary Fibrosis},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {10},
doi = {10.1111/jcmm.71168}
}
EUVIMED